Metachromatic leukodystrophy: 2026 so far

Long-term data made the timing of pre-symptomatic HSCT look especially important.

New long-term European registry data reported that allogeneic HSCT (donor stem cell transplant) was linked to slower progression in late-onset MLD. The strongest pattern was seen when HSCT happened before symptoms began. HSCT was also reported to be associated with better patient-reported quality-of-life and daily-life functioning compared with no HSCT. The biggest benefits were in the pre-symptomatic group. The same dataset also emphasized that HSCT did not always stop symptoms from getting worse. This helps families set more realistic expectations about what HSCT might and might not do, and how much timing may affect results.

Research covered in: September 2026

Reports added specific details about how MLD affects the whole household.

In the months covered, small parent-focused studies described the day-to-day impact of MLD on families, beyond medical visits. One study in France reported a months-long path to diagnosis (about 10 months on average). It also reported substantial hands-on caregiving time (about 6 hours/day on average), with reported effects on work, social life, and emotional well-being. A separate interview study described siblings as sometimes taking on 'helper' roles. It also described siblings experiencing fear, sadness, anger, and school impacts, and highlighted the value of honest, age-appropriate information and sibling-inclusive support. These reports mainly support planning and conversations about practical and emotional support, rather than changing medical treatment decisions.

Research covered in: February 2026, May 2026

New tools aimed to make measurement more consistent, while other work warned about MRI interpretation traps.

Several reports looked at ways to measure MLD progression more consistently in research, and also pointed out pitfalls in interpreting imaging numbers. An automated MRI tool (nnU-Net, a type of AI image-segmentation method) was reported to quantify demyelination (loss of the nerve's protective myelin coating) in a way that closely matched expert methods. It also related more strongly to motor impairment than a conventional semi-automated approach, with stable change over repeated scans. Other work cautioned that intracranial volume (the space inside the skull) and skull thickness can change over time in MLD, which can complicate brain-volume normalization. It also noted that MLD may show relative preservation or even larger regional brain volumes on growth-chart comparisons, rather than a simple steady shrinkage pattern. Separately, an AI system estimated GMFC-MLD motor scores (a scale for movement and walking ability in MLD) from de-identified clinic videos, with accuracy reported specifically on visits where expert raters fully agreed. In the near term, this mainly affects how studies and trials measure change, since more standardized tracking could improve comparisons even though routine clinical use and interpretation are still uncertain.

Research covered in: February 2026, March 2026, April 2026, June 2026, August 2026

Reports described practical screening pathways and highlighted situations where diagnosis is not straightforward.

So far in 2026, earlier identification was discussed through both real-world screening workflows and modeling. Reports also reminded clinicians that MLD-like presentations can be hard to sort out. A newborn screening pilot in Lombardy, Italy demonstrated a three-tier approach (dried-blood-spot marker, enzyme testing, then sequencing when needed). It reported that retesting was sometimes required. It found no MLD cases in its first year. It also noted that some newborns carried variants linked to lower enzyme activity, which complicated interpretation. A US decision-analytic model (a computer model comparing 'what-if' scenarios) projected that newborn screening would identify more early-onset cases than symptom-based diagnosis. It also projected more children surviving without motor impairment around five years after symptom onset (model outputs, not real-world results). Case-based reports also showed that late-onset MLD can resemble multiple system atrophy (a progressive brain disorder affecting movement and autonomic functions). They also showed that an MLD-like picture can occur with normal arylsulfatase A activity, where a PSAP variant raised the possibility of saposin B deficiency (variant classified as uncertain). This gives families a clearer sense of what screening and diagnostic pathways may involve, and why genetic testing may be needed when symptoms and enzyme tests do not match.

Research covered in: January 2026, March 2026, July 2026, August 2026

The months covered added detail on health issues beyond the nervous system and on risks during serious infections.

The available reports expanded the clinical picture of MLD to include non-neurologic issues and risks during severe illness. A systematic review found gallbladder abnormalities were frequently reported in published MLD cases. These were described across the MLD spectrum, and were reported both before neurologic diagnosis and after disease-modifying treatment in some reports. An earlier single-child report also described sulfatide buildup in gallbladder tissue alongside a rare gallbladder cancer, with unclear broader meaning. Separately, a large US electronic health record analysis suggested higher odds of COVID-19 hospitalization in MLD. One-year survival after hospitalization was similar to matched controls for lysosomal storage disorders overall (not reported separately for MLD). A pediatric inpatient database study across many leukodystrophies reported inpatient mortality. It noted deaths were more common with ICU care, infections, and mechanical ventilation, with MLD representing a substantial portion of recorded inpatient deaths in that dataset. Together, these findings add context for monitoring and risk discussions that may need to include whole-body health and severe-illness planning, not only neurologic symptoms.

Research covered in: January 2026, July 2026, September 2026